Get the Stockscreener App
7.84
0.63%
-0.05
Arvinas Inc stock is traded at $7.84, with a volume of 1.59M.
It is down -0.63% in the last 24 hours and up +0.51% over the past month.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
See More
Previous Close:
$7.89
Open:
$7.94
24h Volume:
1.59M
Relative Volume:
0.68
Market Cap:
$572.25M
Revenue:
$161.10M
Net Income/Loss:
$-308.60M
P/E Ratio:
-1.6788
EPS:
-4.67
Net Cash Flow:
$-259.90M
1W Performance:
+6.67%
1M Performance:
+0.51%
6M Performance:
-56.78%
1Y Performance:
-73.44%
1-Day Range:
$7.69
$7.99
1-Week Range:
$7.37
$8.05
52-Week Range:
$5.90
$30.24
Arvinas Inc Stock (ARVN) Company Profile
Name
Arvinas Inc
Sector
Industry
Phone
203-535-1456
Address
395 WINCHESTER AVE, NEW HAVEN, CT
Compare ARVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
7.84 | 575.90M | 161.10M | -308.60M | -259.90M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| May-05-25 | Downgrade | Truist | Buy → Hold |
| May-02-25 | Downgrade | Jefferies | Buy → Hold |
| May-02-25 | Downgrade | TD Cowen | Buy → Hold |
| Mar-13-25 | Downgrade | Goldman | Buy → Neutral |
| Mar-12-25 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-11-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| Feb-14-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-01-24 | Initiated | Goldman | Buy |
| Dec-19-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-06-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-20-23 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Jan-12-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-22 | Initiated | Barclays | Overweight |
| Jun-21-22 | Initiated | Jefferies | Hold |
| May-09-22 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Apr-06-22 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-11-22 | Resumed | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Wells Fargo | Overweight |
| Jan-19-22 | Initiated | Goldman | Buy |
| Dec-07-21 | Initiated | Cowen | Outperform |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-09-21 | Initiated | BofA Securities | Buy |
| May-21-21 | Initiated | UBS | Buy |
| Apr-21-21 | Initiated | Truist | Buy |
| Mar-31-21 | Initiated | BMO Capital Markets | Outperform |
| Dec-14-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-01-20 | Upgrade | Citigroup | Neutral → Buy |
| May-12-20 | Initiated | Oppenheimer | Perform |
| Dec-19-19 | Initiated | H.C. Wainwright | Buy |
| Nov-25-19 | Initiated | Guggenheim | Buy |
| Oct-24-19 | Upgrade | Goldman | Neutral → Buy |
| Sep-25-19 | Initiated | Wedbush | Outperform |
| Sep-12-19 | Initiated | BMO Capital Markets | Outperform |
| Aug-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-05-19 | Downgrade | Citigroup | Buy → Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Oct-22-18 | Initiated | Citigroup | Buy |
| Oct-22-18 | Initiated | Goldman | Neutral |
| Oct-22-18 | Initiated | Piper Jaffray | Overweight |
View All
Arvinas Inc Stock (ARVN) Latest News
What drives Arvinas Inc. stock priceFree Trend-Following Techniques - PrintWeekIndia
What analysts say about Arvinas Inc. stockLightning-fast growth - Autocar Professional
How high can Arvinas Inc. stock price go in 2025Skyrocketing investment returns - jammulinksnews.com
Arvinas (ARVN) to Release Quarterly Earnings on Tuesday - MarketBeat
Is Arvinas Inc. a good long term investmentFree Buy/Sell Signal Notifications - Autocar Professional
Arvinas, Inc. (ARVN): A Bull Case Theory - Insider Monkey
Arvinas Inc. Stock Analysis and ForecastPhenomenal trading returns - Autocar Professional
Arvinas Presents Promising Preclinical Data for BCL6 Degrader ARV-393 in Lymphoma Treatment - MSN
Arvinas, Inc. (NASDAQ:ARVN) Receives $20.29 Consensus Price Target from Analysts - MarketBeat
13 Best Low Priced Pharma Stocks to Buy Now - Insider Monkey
(ARVN) Proactive Strategies - news.stocktradersdaily.com
Arvinas (NASDAQ:ARVN) Trading Down 4.6%Here's Why - MarketBeat
Arvinas: A Potential 'Sum Of The Parts' Story (NASDAQ:ARVN) - Seeking Alpha
Arvinas CEO John Houston to retire - MSN
Arvinas stock slides after eliminating trials, reducing workforce - MSN
Arvinas CEO John Houston to retire, remain as board chair By Investing.com - Investing.com South Africa
Becton Dickinson, Spotify, Arvinas, Twilio, Lumen: Trending by Analysts - MSN
Arvinas (ARVN) Soars 2.62% on CEO Transition - AInvest
Arvinas CEO John Houston to retire, remain as board chair - Investing.com Australia
Gilead signs lenacapavir access deal; Arvinas CEO to step down - BioPharma Dive
Arvinas Announces Retirement of CEO John Houston, Ph.D., - citybiz
Arvinas CEO John Houston to retire after successor is named, will remain board chair - Investing.com Nigeria
Arvinas CEO John Houston to retire after successor is named, will remain board chair By Investing.com - Investing.com South Africa
Arvinas' CEO to Retire; Search for Successor Begins - MarketScreener
Arvinas Announces Retirement of Chief Executive Officer and Succession Plan - The Manila Times
Pioneering Biotech CEO Steps Down: How Arvinas' Houston Transformed Protein Degradation Drug Development - Stock Titan
Arvinas announces board resignation and reports annual meeting voting results By Investing.com - Investing.com South Africa
Arvinas, Inc. Announces John Young Decides to Resign from its Board of Directors and Compensation Committee, Effective June 30, 2025 - MarketScreener
Arvinas announces board resignation and reports annual meeting voting results - Investing.com
Arvinas Inc Stock (ARVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):